English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/100154
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

Modulation of estrogen and epidermal growth factor receptors by rosemary extract in breast cancer cells

AuthorsGonzález-Vallinas, Margarita; Molina, Susana; Vicente, G. ; Sánchez-Martínez, Ruth; Vargas, Teodoro; Rodríguez García-Risco, Mónica ; Fornari, Tiziana ; Reglero, Guillermo ; Ramírez de Molina, Ana
KeywordsEstrogen receptor alpha
Human epidermal growth factor receptor-2
Paclitaxel
Rosemary
Breast cancer
Issue Date2014
PublisherWiley-VCH
CitationElectrophoresis 35(11): 1719-1727 (2014)
AbstractBreast cancer is the leading cause of cancer-related mortality among females worldwide, and therefore the development of new therapeutic approaches is still needed. Rosemary (Rosmarinus officinalis L.) extract possesses antitumor properties against tumor cells from several organs, including breast. However, in order to apply it as a complementary therapeutic agent in breast cancer, more information is needed regarding the sensitivity of the different breast tumor subtypes and its effect in combination with the currently used chemotherapy. Here, we analyzed the antitumor activities of a supercritical fluid rosemary extract (SFRE) in different breast cancer cells, and used a genomic approach to explore its effect on the modulation of ER-α and HER2 signaling pathways, the most important mitogen pathways related to breast cancer progression. We found that SFRE exerts antitumor activity against breast cancer cells from different tumor subtypes and the downregulation of ER-α and HER2 receptors by SFRE might be involved in its antitumor effect against estrogen-dependent (ER+) and HER2 overexpressing (HER2+) breast cancer subtypes. Moreover, SFRE significantly enhanced the effect of breast cancer chemotherapy (tamoxifen, trastuzumab, and paclitaxel). Overall, our results support the potential utility of SFRE as a complementary approach in breast cancer therapy. © 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
URIhttp://hdl.handle.net/10261/100154
DOI10.1002/elps.201400011
Identifiersdoi: 10.1002/elps.201400011
e-issn: 1522-2683
issn: 0173-0835
Appears in Collections:(CIAL) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.